A Perspective on Suitability of a Cost-Based Pricing Methodology for Repurposed Orphan Medicines: A Consideration of the Overall Value Proposition

Value Health. 2022 Jan;25(1):157-158. doi: 10.1016/j.jval.2021.06.017. Epub 2021 Sep 7.

Authors

Alla Zozulya Weidenfeller¹, Behruz Eslami², Mariska Van Aswegen², John Gladish³, Rosa Oliveira², Thierry Volle⁴

Affiliations

¹ Lupin Neurosciences, Zug, Switzerland; Lupin Atlantis Holdings SA, Zug, Switzerland. Electronic address: allazweidenfeller@lupin.com.
² Lupin Neurosciences, Zug, Switzerland; Lupin Atlantis Holdings SA, Zug, Switzerland.
³ EPIC Research GmbH, Baar, Switzerland.
⁴ Lupin Atlantis Holdings SA, Zug, Switzerland.

PMID: 35031094
DOI: 10.1016/j.jval.2021.06.017

No abstract available

Publication types

Letter
Comment

MeSH terms

Costs and Cost Analysis
Drug Costs*
Humans
Orphan Drug Production*